We performed a prospective multicentre study to evaluate the efficacy of therapeutic strategies currently used for ocular toxoplasmosis in a large number of patients (n = 106). Treatment was given for at least four weeks and consisted of three triple drug combinations: group 1, pyrimethamine, suiphadiazine and corticosteroids (n = 29); group 2. clindamycin, sulphadiazine and corticosteroids (n = 37); and group 3. cotrimoxazole (trimethoprim and sulphamethoxazole) and corticosteroids (n = 8). Patients with peripheral retinal lesions remained without systemic therapy (group 4, n--32). Patients from group 1 received leucovorin 5 mg twice a week.
Introduction
Ocular toxoplasmosis is the leading case of posterior uveitis and in the majority of cases represents a late manifestation of congenital infection [1, 2] . Toxoplasma organisms invade the retina of the fetus, where they may transform into the cystic form. Toxoplasmic retinitis is thought to occur when the cyst ruptures and liberated parasites multiply in the surrounding cells.
Therapy for toxoplasmosis has not changed during the past 20 years. Since the available agents are ineffective against the tissue cysts, the major aim of therapy remains to stop multiplication of parasites during active retinochoroiditis. The classical treatment includes a synergistic combination of pyrimethamine and sulphonamides [3] . Pyrimethamine, a folic acid antagonist, may cause bone marrow depression with subsequent hematologic complications. Therefore the search for a less toxic means of treating this disease is very important. Clindamycin, a semisynthetic antibiotic, has a less strong antitoxoplasmal effect on animals than pyrimethamine [4, 5] , but was found effective in treatment of human ocular toxoplasmosis [6, 12] . This drug has relatively few side effects. Scattered case reports showed that co-trimoxazole (trimethoprim with sulphamethoxazole) was effective in man [12, 13] . Since ocular toxoplasmosis is a self-limiting disease and the diagnosis is mainly clinical, it is difficult to evaluate the efficacy of separate therapeutical regimens and many various forms of treatment are used. We performed a prospective multicentre study to evaluate and compare the effectiveness of currently used therapeutic strategies in a large group of ocular toxoplasmosis patients.
Patients and methods
This study included 106 consecutive patients with a clinical diagnosis of active toxoplasmic chorioretinitis consulting ophthalmologic departments of five University hospitals in the Netherlands. Patients selected were those, who had a clinical picture of ocular toxoplasmosis characterized by unilateral focal necrotizing retinitis sometimes associated with typical old pigmented scars. Toxoplasma serology was not routinely performed since toxoplasmal antibodies are present in the majority of the [14] . Treatment was given for at least four weeks and consisted of three triple drug combinations (Table 1) : group 1. pyrimethamine, sulphadiazine and corticosteroids (n = 29); group 2. clindamycin, sulphadiazine and corticosteroids (n = 37); and group 3. co-trimoxazole (trimethoprim and sulphamethoxazole) and corticosteroids (n = 8). Patients with peripheral retinal lesions remained without therapy (group 4, n = 32). Pyrimethamine was used in the University hospital of Amsterdam and Leiden, clindamycin in Rotterdam, Groningen and the Free University of Amsterdam; co-trimoxazole was prescribed in the last stage of the trial in all above mentioned participating hospitals. Patients in group 1 received leucovorin 5 mg twice a week. A complete ophthalmologic examination was performed at regular frequent intervals (at least weekly for a period of six weeks) and the following parameters were documented: visual acuity, inflammatory reaction in vitreous and retina, size and location of the retinal lesion.
Fundus photographs were taken before the therapy and thereafter on day 7, 21 and 42. The final evaluation was performed by two independent ophthalmologists in a masked fashion. Criteria for improvement included: 1. diminished inflammatory reaction in the vitreous, 2. better defined margins of the retinal lesion and eventual pigmentation.
Any complications of the treatments used were carefully monitored: all patients were examined by a specialist in internal medicine and blood counts were performed twice a week.
Results
No difference in the duration of inflammatory activity was observed between the treated and untreated patients or between the separate groups of patients treated ( Table 2 ). The most important factor predicting the duration of inflammatory ac- tivity was the size of the retinal focus itself, independently of the therapy given (P < 0.05). Large retinal lesions were associated with longer duration of activity and therefore with increased recovery time.
We evaluated the changes in size of retinal lesion during the follow up (Table 3) . Marked decrease in the size of the retinal focus (decrease of lesion's diameter of more than a half of optic disc's diameter) was observed in 52% of the patients with pyrimethamine therapy, in 32% of the clindamycin patients, in 25% of the co-trimoxazole patients and in 25% of the patients not treated (differences are not significant).
Complications were encountered significantly more frequently in the group of patients receiving triple regimen containing pyrimethamine. Table 4 shows the frequency of side effects, which necessitated a discontinuation of the drugs used. The most frequent side effects were associated with pyrimethamine and included hematologic complications as thrombocytopenia and leucopenia despite leucovorin medication. In one case a hospital admission was required due to the extreme low platelet count (9.000/mm3); this condition normalized spontaneously (with increased dosage of leucovorin) within two weeks. Complications associated with clindamycin consisted of diarrhea attacks and in two cases mild hepatotoxicity was observed. Sulphadiazine-induced side effects included allergic reactions as rash and fever, and possibly also hematologic changes, which could not be discriminated from pyrimethamine toxicity. One patient developed a peptic ulcer and reacted favorably when the corticosteroids were quickly tapered off. All observed adverse reactions were reversible and the side effects diminished when the treatment was discontinued.
Discussion
In this study the duration of the inflammatory activity in ocular toxoplasmosis could not be shortened by the currently used treatments. This finding is in contradiction with frequent reports in the literature concerning the beneficial role of these treatments in patients xOith ocular toxoplasmosis [2] .
A triple combination with pyrimethamine is considered the most effective treatment for toxoplasmosis [15] , but many toxic side effects and recurrences were reported. A less toxic means of treat- ment consists of clindamycin in combination with sulphadiazine and corticosteroids. This clindamycin associated triple combination was repeatedly reported to be effective i'n patients with ocular toxoplasmosis [7, 11] . However, all above mentioned studies did not include control series, which prevented definite conclusions. The presence of untreated controls in our study allows more reliable comparison of treated and untreated patients and probably explains our disappointing findings. Similar findings were reported in a double masked study in a small group of patients [16] . Several cases of fulminarit ocular toxoplasmosis have been described after the use of corticosteroids without antiparasitory drugs [17] . Prolongation of recovery time by corticosteroids in this study is not probable since the duration of activity did not differ in treated and not treated patients. All our treated patients received oral corticosteroids and no systemic therapy was used in untreated patients.
We should realize that other factors than recovery speed may be of importance for the prognosis of ocular toxoplasmosis (recurrence rate, size of the inflammatory focus and its increase or decrease during the treatment, location in the retina and in the depth of retinal layers and occurrence of cystoid macular edema). Since all these above mentioned parameters could not be analysed, the question whether the patients with ocular toxoplasmosis really do not benefit from the therapy and should not be treated can not yet be answered.
This trial has shown a small advantage in patients, who received pyrimethamine compared to other treatments used or to untreated cases. Do the known side effects of pyrimethamine justify its use when the probable benefit is small? We showed a reduction of retinal inflammatory focus in 52% of the pyrimethamine patients as compared to 25% of untreated cases. Our conclusions only apply to the dosages used in this trial and we do not know what effect a larger dose would have. In decisions whether to use pyrimethamine in the individual patient, clinicians will have to judge whether the probable small benefit we have shown outweighs the inconvenience and side effects, including a possible small risk of irreversible bone marrow depression.
The follow up period of our study was too short to compare the recurrence rate associated with the separate therapeutic regimens. Despite this short follow up several recurrences occurred already in all four groups. It is very difficult to compare the efficacy of therapeutic regimens for ocular toxoplasmosis. A conclusive study would require a division of series of retinal lesions in size, location, duration, first attacks and recurrences, which is of course very difficult to realize. Further evaluation of control studies is needed to confirm the value of treatment in ocular toxoplasmosis. Despite the lack of benefit found in our patient groups, our results do support the idea that controlled trials are helpful and provide encouragement for further efforts to identify more selective and less toxic antiparasitory drugs.
